
The company reported higher quarterly revenue, European approvals for two obicetrapib products and plans for key trial updates.
NewAmsterdam Pharma reported a third-quarter net loss of $17.4 million, compared with $72.0 million a year earlier. Revenue increased to $19.2 million from $0.3 million, primarily because of regulatory milestones under its license agreement with Menarini.
The company had $643.1 million in cash, cash equivalents and marketable securities as of September 30, down from $728.9 million at the end of 2025. Research and development expenses rose to $39.4 million from $31.0 million, while selling, general and administrative expenses edged down to $24.0 million from $24.5 million.
In September, the European Commission approved Ubeslo, an obicetrapib-only treatment, and Evlarco, a fixed-dose combination of obicetrapib and ezetimibe. NewAmsterdam said these were the first regulatory approvals of obicetrapib worldwide. Menarini plans to launch the products in Germany by the end of 2026 and in the UK in 2027.
NewAmsterdam said it plans a PREVAIL interim analysis in the fourth quarter of 2026, with results expected in the first quarter of 2027. It also expects top-line data from the RUBENS Phase 3 trial around year-end 2026. The company has begun enrolling participants in SPINOZA, a Phase 2b trial of obicetrapib in preclinical Alzheimer’s disease.
As of Wednesday afternoon, NewAmsterdam shares traded at $20.88, up 4.92% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.